<?xml version="1.0" encoding="UTF-8"?>
<p>Several studies have been undertaken to develop new treatment strategies for viral infections and the use of immunotherapy is encouraging [
 <xref rid="B170-ijms-21-05559" ref-type="bibr">170</xref>]. One of the most useful immunotherapy methods is passive immunity [
 <xref rid="B171-ijms-21-05559" ref-type="bibr">171</xref>], i.e., the transfer of active humoral immunity including ready-made antibodies. There are two main categories of acquired artificial passive immunity against COVID-19: treatment with monoclonal antibodies (mAbs) and convalescent plasma from people recovering from COVID-19 [
 <xref rid="B171-ijms-21-05559" ref-type="bibr">171</xref>]. The antibodies directly bind to the viral antigen and provide an effective anti-viral response. Several monoclonal antibodies are currently being studied or are undergoing clinical trials [
 <xref rid="B172-ijms-21-05559" ref-type="bibr">172</xref>].
</p>
